logo
  

Bristol Myers Reports FDA Priority Review For Relatlimab And Nivolumab Combination

Bristol Myers Squibb (BMY) said FDA has accepted for priority review the Biologics License Application for relatlimab and nivolumab fixed-dose combination in the treatment of adult and pediatric patients with unresectable or metastatic melanoma. The BLA submission was based on the efficacy and safety results of the phase 2/3 RELATIVITY-047 trial. The FDA assigned a PDUFA goal date of March 19, 2022.

Bristol Myers Squibb is currently evaluating relatlimab, LAG-3-blocking antibody, in clinical trials in combination with other agents in a variety of tumor types.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Royal Caribbean Group's ultra-luxury brand Silversea Cruises is set to launch the world's first hybrid-powered cruise ship in the summer of 2023. This will also be the first ship with large-scale fuel cell technology to enable emission-free port operations. The fuel cells will provide 100% of power while at port. Affco USA is recalling around 24,461 pounds of frozen raw lamb shoulder products that were not presented for import re-inspection into the U.S., the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS announced. The recall involves the frozen raw lamb shoulder items that were imported on July 12, 2021. American Express Company (AXP) reported an increase in profit for the third quarter that also topped Wall Street estimates. Consolidated total revenues net of interest expense rose 25 percent year-on-year, primarily reflecting growth in Card Member spending, as well as a rise in the average discount...
Follow RTT